Skip to main content
Back
Watch Compare

Immuneering Corp

Data quality: 83%
IMRX
Nasdaq Manufacturing Chemicals
$5.52
▼ $0.14 (-2.47%)
Mkt Cap: 358.82 M
Price
$5.55
Mkt Cap
358.82 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -45.49 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-43.61%
Above sector avg (-53.34%)
ROIC-35.52%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio24.00
Interest CoverageN/A

Valuation

PE (TTM)
-6.40
Below sector avg (-1.47)
P/B Ratio1.57
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -6.4 -1.5
P/B 1.6 1.6
ROE % -43.6 -53.3
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

6 analysts
Buy
Current
$5.52
+208.0%
Target
$17.00
$11.00
$14.50
$30.00
Forecast
Forward P/E -4.08
Forward EPS -$1.35
Est. Revenue 19.20 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$1.35
-$1.73 – -$0.67
 19.20 M 6
FY2026 -$1.19
-$1.37 – -$0.99
 0.0 6

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.31 -$0.18 +42.3%
Q32025 -$0.39 -$0.38 +2.2%
Q22025 -$0.40 -$0.40 -0.5%
Q12025 -$0.59 -$0.42 +28.2%

ETFs Holding This Stock

CNCR CNCR
1.01% weight
BRUSX BRUSX
0.44% weight
BRSIX BRSIX
0.08% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -56.02 M
ROE -43.61% ROA -39.86%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45.49 M
ROIC -35.52% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 24.00
Interest Coverage N/A Asset Turnover N/A
Working Capital 219.56 M Tangible Book Value 220.96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -6.40 Forward P/E N/A
P/B Ratio 1.57 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -12.68%
Market Cap 358.82 M Enterprise Value 131.26 M
Per Share
EPS (Diluted TTM) -1.27 Revenue / Share N/A
FCF / Share -0.70 OCF / Share -0.70
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 81.19%
SBC-Adj. FCF -51.80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — 0.0 316,952.0 2.08 M
Net Income -56.02 M -61.04 M -53.47 M -50.51 M -33.54 M
EPS (Diluted) -1.27 -2.04 -1.88 -1.90 -2.46
Gross Profit — — 0.0 158,830.0 926,888.0
Operating Income -59.38 M -64.07 M -58.41 M -51.74 M -33.89 M
EBITDA — — — — —
R&D Expenses 42.05 M 47.96 M 41.62 M 36.27 M 26.54 M
SG&A Expenses — — — — —
D&A 324,517.0 355,807.0 — — —
Interest Expense — — — — —
Income Tax 0.0 — — -307,485.0 -307,485.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 231.99 M 52.71 M 102.58 M 122.37 M 166.70 M
Total Liabilities 13.50 M 11.33 M 12.01 M 12.52 M 10.72 M
Shareholders' Equity 218.48 M 41.39 M 90.58 M 109.85 M 155.98 M
Total Debt — — — — —
Cash & Equivalents 128.65 M 36.14 M 59.41 M 72.64 M 74.89 M
Current Assets 176.25 M 39.59 M 89.08 M 108.75 M 152.33 M
Current Liabilities 10.07 M 7.50 M 7.85 M 8.05 M 5.63 M